Category
Glp 1
10 articles
Australia Obesity Statistics 2026: Rates, Trends & Costs
Australia obesity statistics 2026: about two in three adults overweight or obese (roughly a third obese), one in four children affected, $11.8B in costs. State data since 1995.
Telehealth Prescribing of Schedule 4 Peptides: 2026 Brief
Telehealth is permanent in Australian healthcare, but its overlap with Schedule 4 peptide prescribing is under-examined. The framework, gaps, and priorities.
State of Metabolic Health in Australia 2026: Evidence Report
Metabolic health in Australia, 2026: overweight or obesity affects about 67% of adults (roughly 31% obese), 1.3 million live with diabetes, and direct obesity costs run to $11.8 billion. A reform reference.
Childhood Obesity in Australia: Why 'Eat Less' Failed
One in four Australian children lives with overweight or obesity. Why individual-responsibility campaigns failed, and what real food reform could achieve.
Type 2 Diabetes in Australia: Prevalence, Cost and Policy
Type 2 diabetes Australia statistics: 1.2 million diagnosed, $4.4 billion in annual health expenditure, and deep equity gaps demanding urgent policy reform.
Weight Stigma in Australian Healthcare: Evidence and Policy
How weight stigma in Australian healthcare policy deters care, drives worse outcomes, and what clinician bias training and GLP-1 era reframing can change.
Bariatric Surgery Access in Australia: A Two-Tiered System
Australia's bariatric surgery system splits sharply by income, leaving public patients waiting years as GLP-1 drugs reshape demand. Access barriers and reform.
GLP-1 Shortages in Australia: Policy Failures Exposed
Australia's GLP-1 shortage exposes deep gaps in medicines policy. The supply crisis, access inequities, the compounding debate, and six reforms needed.
Medicare and PBS Reform for Obesity Treatment in Australia
Australia's PBS coverage of obesity medication lags the clinical evidence and leaves treatment inequitable. The case for expanded GLP-1 listing and reform.
Metabolic Syndrome in Australia: Evidence Meets Policy
Australia's metabolic syndrome burden is large and growing, but Medicare and policy haven't kept pace. The gap between what research shows and what's delivered.